IGX - IntelGenx Technologies Corp. Stock Price, News & Analysis

C$0.90 0.01 (1.12 %)
(As of 11/23/2017 02:08 AM ET)
Previous CloseC$0.89
Today's RangeC$0.89 - C$0.90
52-Week RangeC$0.79 - C$1.39
Volume2,500 shs
Average Volume19,686 shs
Market CapitalizationC$57.25 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.02

About IntelGenx Technologies Corp. (CVE:IGX)

IntelGenx Technologies Corp. logoIntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company’s products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimer’s disease. It is also developing various products, including INT0037/2013, INT0039/2013, INT0040/2014, INT0041/2015, INT0042/2015, and INT0044/2016 based on three delivery platform technologies, which consist of VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology; and AdVersa, a mucoadhesive tablet technology. The company has co-development and commercialization agreements with RedHill Biopharma Ltd.; Par Pharmaceutical Companies, Inc.; and Endo Ventures Ltd., as well as a licensing, development, and supply agreement with Chemo Group. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Saint-Laurent, Canada.


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealthcare
SymbolCVE:IGX
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares66,837,000

Frequently Asked Questions for IntelGenx Technologies Corp. (CVE:IGX)

What is IntelGenx Technologies Corp.'s stock symbol?

IntelGenx Technologies Corp. trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IGX."

When will IntelGenx Technologies Corp. make its next earnings announcement?

IntelGenx Technologies Corp. is scheduled to release their next quarterly earnings announcement on Tuesday, March, 27th 2018. View Earnings Estimates for IntelGenx Technologies Corp..

Who are some of IntelGenx Technologies Corp.'s key competitors?

How do I buy IntelGenx Technologies Corp. stock?

Shares of IntelGenx Technologies Corp. and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is IntelGenx Technologies Corp.'s stock price today?

One share of IntelGenx Technologies Corp. stock can currently be purchased for approximately C$0.90.

How big of a company is IntelGenx Technologies Corp.?

IntelGenx Technologies Corp. has a market capitalization of C$57.25 million.


MarketBeat Community Rating for IntelGenx Technologies Corp. (IGX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  4 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  7
MarketBeat's community ratings are surveys of what our community members think about IntelGenx Technologies Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for IntelGenx Technologies Corp. (CVE:IGX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for IntelGenx Technologies Corp. (CVE:IGX)

Price Target History for IntelGenx Technologies Corp. (CVE:IGX)

Analysts' Ratings History for IntelGenx Technologies Corp. (CVE:IGX)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for IntelGenx Technologies Corp. (CVE:IGX)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for IntelGenx Technologies Corp. (CVE:IGX)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for IntelGenx Technologies Corp. (CVE:IGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for IntelGenx Technologies Corp. (CVE IGX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for IntelGenx Technologies Corp. (CVE IGX)

Source:
DateHeadline
IntelGenx Submits Montelukast VersaFilm Clinical Trial Application With Health CanadaIntelGenx Submits Montelukast VersaFilm Clinical Trial Application With Health Canada
www.finanznachrichten.de - November 11 at 11:41 AM
Intelgenx Technologies Corp. (IGX) to Release Earnings on ThursdayIntelgenx Technologies Corp. (IGX) to Release Earnings on Thursday
www.americanbankingnews.com - November 3 at 10:58 AM
IntelGenX Technologies Corp. (IGX) Scheduled to Post Earnings on ThursdayIntelGenX Technologies Corp. (IGX) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - August 4 at 3:32 PM

Social Media

Financials

Financials are not available for this stock.

Chart

IntelGenx Technologies Corp. (CVE IGX) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.